[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-breast\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-breast":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,105,140,219,241,270,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100461484","unified-barlow-protocol-up-in-cancer-survivors-for-cognitive-impairments-100461484",false,"NCT05289258","Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments","Effectiveness of Cognitive Rehabilitation and the Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Cancer diagnosis, stages I-III.\n* Cancer type: Breast.\n* Have received the last chemotherapy session in the last 6 months and a maximum of 6 years of treatment completion.\n* Probable or mild to moderate cognitive impairment (score between 26 and 10 points according to the MMSE).\n* Ability to be fluent in Spanish.\n* Not currently participating in another clinical trial.\n* Not currently receiving other psychological treatment\n\nExclusion Criteria:\n\n* Men and women aged \\> 70 years.\n* Diagnosis of cancer, stage IV or other types of cancer.\n* Last chemotherapy session \\\u003C 6 months or \\> 6 years.\n* No cognitive impairment (MMSE score between 30 and 27 points).\n* Diagnosis of mental disorder (including substance abuse) prior to cancer diagnosis.\n* Relapse in disease after chemotherapy treatment is completed.\n* Neurodevelopmental Disorder Diagnosis.\n* Diagnosis of diseases that affect cognitive performance such as: hypertension, cardiac diseases, epilepsy, dementias, multiple sclerosis, functional disorders (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, post-concussion syndrome, whiplash syndrome), CNS infections (HIV, encephalitis), metabolic disorders (diabetes, B12 deficiency), obstructive sleep apnea, brain damage (stroke, TBI, CNS cancer) and use of medications \u002F substances that interfere with cognitive function such as pregabalin, gabapentin, topiramate, antidepressants tricyclics, sodium valproate, anticholinergics, methylphenidate, typical antipsychotics.","ALL","18 Years","70 Years",{"count":20,"type":21},123,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background: Cognitive impairment appears frequently in cancer survivors, negatively affecting the quality of life and emotional well-being of patients. This study compares the effectiveness of a well-established treatment (cognitive rehabilitation) with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to alleviate these cognitive deficits and evaluate its effect on anxiety-depressive symptoms and the quality of life of survivors.\n\nMethods: A three-arm randomized superiority clinical trial, with a pre-post and follow-up repeated measures and intergroup design with a 1:1:1 allocation ratio will be carried out. A hundred and twenty-three breast cancer survivors with mild to moderate cognitive impairment will be randomly assigned to one of the interventions of the study: cognitive rehabilitation intervention group, an intervention group with UP intervention, or a control group on the waiting list. The primary outcome is to observe a significant improvement in cognitive function and quality of life in both intervention groups and a significant decrease in emotional impairments in comparison with the waitlist group. These results will be maintained at six months of follow-up.\n\nDiscussion: The aim of this work is to test the efficacy of the Unified Barlow Protocol in reducing cognitive deficits in breast cancer survivors. The results of this trial may be useful in reducing the presence of cognitive problems in survivors and improving their emotional state and quality of life.",[27],"Cancer, Breast",[29,30,31,32],"Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)","cognitive impairments","quality of life","anxiety and depression.","RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2021-01-25",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Universidad de Córdoba","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100536733","phase-2-tart-cherry-juice-as-a-dietary-supplement-for-the-prevention-of-paclitaxel-induced-neuropathy-100536733","NCT06268665","Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","Inclusion Criteria:\n\n* Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.\n* Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.\n\n  * Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.\n  * Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.\n  * Concurrent use of immune checkpoint inhibitor therapy is allowed.\n  * (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed.\n  * Concurrent use of carboplatin with weekly paclitaxel in the study is allowed.\n* May participate concurrently in other cancer trials.\n* Must be able to complete questionnaires in English or Spanish.\n* Age ≥ 18 years old at the time of consent.\n* ECOG performance status of 0 - 1 (Karnofsky scale ≥ 70%, see Appendix).\n* Ability to understand and the willingness to sign a written informed consent document.\n* Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation).\n* Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells\u002FµL and an undetectable HIV viral load on standard PCR-based tests within the last year.\n* Stated willingness to not drink any additional tart cherry or any cherry juice while on the study.\n* Ability and willingness to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (≥ 2 week washout period required).\n* Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus.\n* Currently taking anticoagulant medication.\n* Currently taking Vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements\u002Fmedications, they must agree to stop at the time of registration. Multivitamins containing Vitamin E are allowed, however Vitamin E \\> 1,000 international units (IU) must be discontinued at the time of registration.\n* Patients may not use cold therapy gloves for chemotherapy induced neuropathy.\n* Known allergy to cherries.\n* Inability to swallow liquid.\n* Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation).\n* Any condition that would prohibit the understanding or rendering of informed consent.\n* Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial.",{"count":54,"type":21},86,[56],"PHASE2","This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy.\n\nEligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,27,85,86,87,88,89,90,91,92,93,94],"Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Stage IV","Invasive Breast Cancer","Ovarian Cancer","Ovarian Cancer Stage 1","Ovarian Cancer Stage II","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Ovarian Cancer Stage IA","Ovarian Cancer Stage IB","Ovarian Cancer Stage IC","Ovarian Cancer Stage 2","Ovarian Cancer Stage 3","Ovarian Cancer Stage IIIb","Ovarian Cancer Stage IIIC","Breast Cancer Stage IIIA","Breast Cancer Invasive","Breast Cancer, Stage IA","Breast Cancer, Stage IB","Breast Cancer Stage IIA","Breast Cancer Stage IIB","Breast Cancer Stage IIIB","Breast Cancer Stage IIIc","Tumors, Breast","Mammary Cancer","Mammary Carcinoma","Breast Carcinoma","Breast Neoplasm","Malignant Breast Neoplasm","Malignant Tumor of Breast","Cancer of Ovary","Ovary Cancer","Ovary Neoplasm","2026-03-02",{"date":97,"type":37},"2026-03-04",{"date":99,"type":37},"2024-08-15",{"date":101,"type":21},"2027-12",{"name":103,"class":44},"University of California, Davis",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":104},"100494730","with-love-grandma-con-cario-abuelita-pilot-study-100494730","NCT05721976","With Love, Grandma (\"Con Cariño, Abuelita\") Pilot Study","Pilot Study of a Multigenerational Digital Lifestyle Intervention for Hispanic Female Cancer Survivors and Their Families","Cancer Survivor Inclusion Criteria:\n\n* Grandmother\n* Self-identifies as Hispanic\n* Diagnosis of breast cancer (stages I-III), endometrial or ovarian cancer (stages I-II)\n* Completed active treatment (i.e., surgery, chemotherapy, and\u002For radiation)\n* Body Mass Index (BMI) ≥ 25 (overweight range)\n* Engages in \\\u003C150 minutes\u002Fweek of moderate physical activity\n* English or Spanish speaking\n* Owns a mobile device with internet access (e.g., smartphone, tablet)\n* Lives in South Florida\n\nDaughter of Cancer Survivor Inclusion Criteria:\n\n* Adult daughter of the identified cancer survivor (21 years of age or older)\n* Has at least 1 living child ages ≤16 years old\n* Body Mass Index (BMI) ≥ 25 (overweight range) OR engages in \\\u003C150 minutes\u002Fweek of moderate physical activity\n* English or Spanish speaking\n* Owns a mobile device with internet access (e.g., smartphone, tablet)\n* Lives in South Florida\n\nDaughter of Cancer Survivor Exclusion Criteria:\n\n* Has been diagnosed with distant metastatic cancer\n* Has not completed active treatment (i.e., surgery, chemotherapy, and\u002For radiation)\n* Has uncontrolled schizophrenia or bipolar disorder\n* Has a preexisting medical condition that precludes unsupervised physical activity (e.g., severe orthopedic conditions,wheelchair bound).\n\nCancer Survivor Exclusion Criteria:\n\n* Has uncontrolled schizophrenia or bipolar disorder\n* Has a preexisting medical condition that precludes unsupervised physical activity (e.g., severe orthopedic conditions, wheelchair bound)","FEMALE","21 Years",{"count":115,"type":21},60,[24],"The purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors (physical activity, dietary intake) among Hispanic female cancer survivors and adult daughters.",[27,119,120,121,122,123],"Cancer, Uterus","Cancer, Ovary","Obesity","Activity, Motor","Diet, Healthy",[125,126,127,128,129,130],"Hispanic","family","digital health","cancer survivorship","physical activity","nutrition","2026-02-24",{"date":133,"type":37},"2026-02-25",{"date":135,"type":37},"2023-02-22",{"date":137,"type":21},"2026-12-31",{"name":139,"class":44},"University of Miami Sylvester Comprehensive Cancer Center",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":192,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":218},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":147,"type":21},50000,"36 Months","OBSERVATIONAL","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[152,153,154,155,156,157,158,159,160,161,162,163,164,27,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,65,182,183,59,184,185,186,187,188,189,190,191],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Endometrial Cancer","Testicular Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[193,194,195,196,197,198,199,200,201,202,203,204,205,206,207],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":210,"type":37},"2025-10-28",{"date":212,"type":37},"2018-01-01",{"date":214,"type":21},"2040-06",{"name":216,"class":217},"Massive Bio, Inc.","INDUSTRY",68,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":45},"100567740","exercise-in-triple--negative-breast-cancer-100567740","NCT06672120","Exercise in Triple- Negative Breast Cancer","Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition","ExACT-ICI","Inclusion Criteria:\n\n* Female patients with newly diagnosed, local triple-negative breast cancer (stage I-III) ≥ 18 to 65 years of age scheduled for immunochemotherapy with pembrolizumab and anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Unstable cardiac condition (clinical suspicion of progress or unstable coronary artery disease, signs of acute heart failure, haemodynamically relevant arrhythmias)\n* Orthopaedic disability to exercise","65 Years",{"count":229,"type":21},120,[24],"This is a prospective, randomized, controlled mono-center study investigating the effects of a combined, supervised aerobic exercise and resistance training in female patients with newly diagnosed, therapy-naive triple-negative breast cancer (TNBC, stage I-III) between 18 and 50 years of age scheduled for anthracycline-based chemotherapy and immunotherapy with checkpoint inhibitors. All patients will receive smart watches for rhythm monitoring.\n\nPatients will be randomized (1:1) into a control group, receiving 24 weeks of standard exercise recommendations during neoadjuvant therapy, and an intervention group receiving 24 weeks of home-based, video-supervised exercise training consisting of endurance and resistance training. The primary endpoint is the change of peak oxygen consumption (VO2peak) between baseline and 24 weeks in the groups. Secondary endpoints include changes of physical function (short physical performance battery, SPPB), as well as cardiac biomarkers, quality of life, and changes of strength of the upper and lower body between baseline and 24 weeks. In addition, variables of cardiopulmonary exercise testing (CPET), resting and stress echocardiography, and burden of atrial fibrillation (AF) will be assessed. All changes in variables will be analyzed from baseline until 52 weeks as well.\n\nBoth groups will receive standard exercise recommendations after 24 weeks and will be followed-up by clinical examination after 52 weeks. Echocardiographic variables (at rest and during exercise), quality of life, CPET, SPPB, strength testing, burden of AF, and cardiac biomarkers will be assessed. Changes between the end of the intervention period 24 weeks after diagnosis and the end of follow-up after 52 weeks will be analyzed. In addition, changes in variables between baseline and 52 weeks will be analyzed.\n\nAs an exploratory endpoint the incidence of cancer therapy-related cardiac dysfunction (CTRCD) and immune-checkpoint inhibitor- associated myocarditis (ICI-myocarditis) will be assessed after 24 and 52 weeks.",[27],"2025-05-27",{"date":235,"type":37},"2025-05-31",{"date":237,"type":37},"2025-04-03",{"date":41,"type":21},{"name":240,"class":44},"Technical University of Munich",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":112,"minAge":250,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":104},"100320403","older-breast-cancer-patients-risk-for-cognitive-decline-100320403","NCT03451383","Older Breast Cancer Patients: Risk for Cognitive Decline","Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study","TLC","Inclusion Criteria:\n\nFor cancer patients, eligibility includes:\n\n* being female\n* Age 60+ at diagnosis of a new primary histological confirmed adenocarcinoma breast cancer\n* AJCC stages 0-3 or planning neoadjuvant therapy\n* In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent\n* If currently taking psychoactive medications (including, but not limited to anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at least two months prior to enrollment.\n* Participant report of no previous or current chemotherapy or hormonal treatment use (anastrazole, exemestane, etc.) This does not include hormonal replacement therapy, synthetic thyroid hormones, etc.\n\nFor controls, eligibility includes:\n\n* being female\n* Age 60+\n* In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent\n* If currently taking psychoactive medications (including, but not limited to anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at least two months prior to enrollment.\n\nExclusion:\n\nWe apply the same exclusion criteria for patients and controls.\n\n* Participant report of a history of formal diagnosis of neurological problems (i.e. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, brain tumors, etc.)\n* Participant report of surgery on the brain for any reason (cancerous or non-cancerous tumors, subdural hematomas, AV malformations, increased intracranial pressure, etc.)\n* Participant report of a history of stroke (with the exception of TIA if ≥1 year ago)\n* Participant report of HIV\u002FAIDS\n* Participant report of moderate to severe head trauma (loss of consciousness \\> 60 min or with evidence of structural brain changes on imaging)\n* History of major psychiatric disorder (DSM-IV Axis 1) (i.e. major depressive disorder (untreated or poorly treated), bipolar disorders, schizophrenia, or substance abuse disorders (self-reported and\u002For stated in medical record).\n* Participant report of a history of prior breast or other cancer with the exception of non-melanoma skin cancer. An exception for cases only: women who completed treatment for a previous cancer at least 5 years ago and have not undergone any chemotherapy or hormonal therapy. This previous cancer cannot be breast cancer.\n* Participant report of previous or current chemotherapy or hormonal therapy use\n* Participant use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for Lupus.\n* Visual or hearing impairment that would preclude ability to complete interviews or neuropsychological testing, such as significant macular degeneration or being unable to correct hearing with hearing aides\n* Non-English speaking\n* To participate in the optional neuroimaging portion of the study:\n\nParticipant cannot be claustrophobic Participant cannot have a pacemaker, aneurysm clip or other implants that are not MRI safe Participant cannot have any type of implanted electrical device",true,"60 Years","105 Years",{"count":253,"type":21},1700,"The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.",[27,256,257],"Age-related Cognitive Decline","Cognitive Decline",[259,260],"breast cancer","cognitive decline","2025-03-10",{"date":263,"type":37},"2025-03-11",{"date":265,"type":37},"2010-08-01",{"date":267,"type":21},"2025-04-30",{"name":269,"class":44},"Georgetown University",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":277,"targetDuration":279,"studyType":149,"phases":4,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":104},"100409197","integrated-patient-avatars-for-guiding-systemic-therapy-treatments-in-metastatic-breast-cancer-patients-100409197","NCT04608357","Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients","Integrated Patient Avatars for Guiding Systemic Therapy Treatments: \"Intuition-Free\" Decisions in Metastatic Breast Cancer Patients","Inclusion Criteria:\n\n1. Age 18+.\n2. Metastatic breast cancer irrespective of subtype.\n3. Measurable disease as per RECIST 1.1 criteria.\n4. Metastatic disease involving the lymph nodes and\u002For visceral organs is required.\n5. Willingness to undergo a biopsy prior to the start of planned systemic therapy.\n\nExclusion Criteria:\n\n1. Lack of feasibility to obtain a core biopsy of a metastatic site other than the bone (e.g. a metastatic lesion cannot be safely sampled due to proximity to vasculature).\n2. Inability to provide informed consent.",{"count":278,"type":21},25,"3 Years","The investigators propose to use clinically validated patient avatar technology (\"PDXovo\") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.",[59,282,283,27],"Breast Neoplasms","Metastatic Breast Cancer",[285,286,287,288,289,290],"metastatic breast cancer","systemic therapy","needle core biopsy","PDXovo","feasibility study","tumor take rate","2025-01-17",{"date":293,"type":37},"2025-01-20",{"date":295,"type":37},"2021-07-21",{"date":101,"type":21},{"name":298,"class":44},"Sunnybrook Health Sciences Centre",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":45},"100542643","fast-forward-vs-hai5-100542643","NCT06345534","FAST-FORWARD vs HAI5","Randomized Comparison Between the FAST-FORWARD Schedule and the HAI5 Schedule for Breast Cancer Radiotherapy in 5 Fractions","Inclusion Criteria:\n\n* histopathological diagnosis of breast cancer\n* age 18 years or older\n* male or female\n* treated with breast conserving surgery or mastectomy with curative intent\n* multidisciplinary decision of adjuvant radiotherapy after surgery\n\nExclusion Criteria:\n\n* distant metastases\n* decision of preoperative radiotherapy\n* decision of partial breast irradiation\n* positive resection margins ('ink on tumour')\n* indication for boost on lymph node(s)\n* history of thoracic or ipsilateral axillary radiotherapy (including radiotherapy of the contralateral breast or chest wall)\n* need for bilateral irradiation\n* breast reconstruction or expander\n* patients unlikely to comply with the protocol (e.g. inability or unwillingness to complete the questionnaires at different time points).",{"count":307,"type":21},740,[24],"Randomized comparison between the FAST-FORWARD schedule and the HAI5 schedule for breast cancer radiotherapy in 5 fractions.",[27],"2024-06-03",{"date":313,"type":37},"2024-06-05",{"date":315,"type":37},"2024-05-30",{"date":317,"type":21},"2033-12-31",{"name":319,"class":44},"University Hospital, Ghent"]